tbuckley/cabot-search huggingface dataset:
Spontaneous Hypoglycaemia
Authors: N. Naish, J. Naish
Journal: BMJ (1946)

<h3>Objective</h3> The aim of this systematic review was to develop a ‘contributory factors framework’ from a synthesis of empirical work which summarises factors contributing to patient safety incidents in hospital settings. <h3>Design</h3> A mixed-methods systematic review of the literature was conducted. <h3>Data sources</h3> Electronic databases (Medline, PsycInfo, ISI Web of knowledge, CINAHL and EMBASE), article reference lists, patient safety websites, registered study databases and author contacts. <h3>Eligibility criteria</h3> Studies were included that reported data from primary research in secondary care aiming to identify the contributory factors to error or threats to patient safety. <h3>Results</h3> 1502 potential articles were identified. 95 papers (representing 83 studies) which met the inclusion criteria were included, and 1676 contributory factors extracted. Initial coding of contributory factors by two independent reviewers resulted in 20 domains (eg, team factors, supervision and leadership). Each contributory factor was then coded by two reviewers to one of these 20 domains. The majority of studies identified active failures (errors and violations) as factors contributing to patient safety incidents. Individual factors, communication, and equipment and supplies were the other most frequently reported factors within the existing evidence base. <h3>Conclusions</h3> This review has culminated in an empirically based framework of the factors contributing to patient safety incidents. This framework has the potential to be applied across hospital settings to improve the identification and prevention of factors that cause harm to patients.
Hyperthyroidism Secondary to Metastatic Functioning Thyroid Carcinoma: A Case Presentation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α2b
Authors: G Saracco
Journal: Hepatology (1993)

Eighty patients with chronic hepatitis C who completed a previously reported randomized controlled trial on the efficacy of interferon-α2b were followed up for at least 36 mo after therapy discontinuation. Seventeen patients (21.2%) maintained normal ALT values throughout the follow-up; 63 (78.8%) either did not normalize the levels of ALT or relapsed during the follow-up. A significantly greater proportion of patients treated with 3 million units of interferon three times a week subcutaneously for 48 wk were long-term responders compared with patients treated for 24 wk. Sex, age, hepatitis C virus antibody status, source of infection and pretreatment levels of ALT were not predictive of long-term response. Cirrhosis was found to be an unfavorable predictive factor. After 3 yr of follow-up, clearance of viremia was observed in 58.9% of the 17 long-term responders but in none of the nonresponders (p = 0.002). E2-NS1 antibody tested negative in 88.2% of long-term responders and in 14.3% of nonresponders (p = 0.001). Fifty-nine percent of long-term responders tested negative for C100-NS4 antibody compared with 14.3% of nonresponders (p = 0.031). No significant change was observed in other antibodies. Four long-term responders underwent liver biopsy 2 yr after discontinuation of therapy. All four patients had normal liver histology compared with baseline assessment of chronic active hepatitis in three and chronic persistent hepatitis in the other. Three of the four were negative for serum hepatitis C virus RNA. (HEPATOLOGY 1993; 18:1300–1305.)
Green Hair
Authors: Richard M. Lampe
Journal: JAMA (1977)

THE APPEARANCE of green hair in a child is as startling to the parent as it is to the physician. Since current literature has little to say about green hair, we report the following two cases. <h3>Report of Cases</h3><h3>Case 1.—</h3> In a 5-year-old blond girl, progressively increasing green discoloration of her hair developed over one weekend. This followed repeated swimming in a motel pool. The green color was peripheral in distribution and was particularly noticeable in the "ponytail" area (Fig 1). The moistened hair felt silky smooth when passed between the fingers. The green color gradually disappeared when she stopped swimming in that particular pool; this return to normal was aided by daily alternate washing with basic and acidic shampoos, and by careful rinsing and drying the hair after swimming. <h3>Case 2.—</h3> In a 6-year-old blond boy, a similar discoloration developed after he swam repeatedly in a different pool.
Myocardial Sarcoidosis
Authors: ROBERT A. PEACOCK, EUGENE J. LIPPSCHUTZ, AGNES LUKAS
Journal: Circulation (1957)

Systemic sarcoidosis frequently involves the heart and is usually diagnosed at autopsy, often as a single granuloma. An extensive review of the literature was prompted by a very interesting clinical problem of etiology in the frequent syncope and Stokes-Adams attacks in an otherwise apparently healthy young girl. The pathologic findings and therapeutic dilemmas are reviewed in detail.
Reply to Ferhat Ates, Ilker Akyol and Hasan Soydan’s Letter to the Editor re: Meelan Bul, Xiaoye Zhu, Antti Rannikko, et al. Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results from a Prospective Observational Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.02.002
Authors: Meelan Bul, Xiaoye Zhu, Monique J. Roobol
Journal: European Urology (2012)
Introduction of mutant &lt;I&gt;p53&lt;/I&gt; into a wild-type &lt;I&gt;p53&lt;/I&gt;-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis
Authors: Julie A. Cerrato, W.K. Alfred Yung, Ta-Jen Liu
Journal: Neuro-Oncology (2001)

Transient expression of the tumor suppressor gene p53 via adenoviral-mediated gene transfer induces apoptosis in glioma cells expressing mutant p53, while causing cell cycle arrest in cells with wild-type p53.To determine whether a change in p53 status of a wild-type p53expressing cell line such as U-87 MG would alter its apoptotic resistant phenotype in response to Ad-p53 infection, we generated cell lines U-87-175.4and U-87-175.13via retroviral-mediated gene transfer of the p53 (175H) mutant into the U-87 MG parental line.Control cell lines U-87-Lux.6 and U-87-Lux.8were also generated and express the reporter gene luciferase.Both U-87-175.4and U-87-175.13,but not control cell lines, exhibited morphology characteristic of apoptosis after Ad-p53 infection.Furthermore, expression of other p53 mutants (248W, 273H) in U-87 MG also sensitized cells to Ad-p53-induced apoptosis.Apoptosis was con rmed by TUNEL and cell cycle analysis.Several p53 response genes were examined in cells infected with Ad-p53, and among these, BCL2, p21 WAF1/CIP1 , CPP32/caspase 3, and PARP showed differences in expression between U87-175 and U87-Lux cell lines.Taken together, our data demonstrate that the introduction of p53 mutants in U-87 MG promotes an apoptotic response in association with adenoviral-mediated wild-type p53 gene transfer.These results underscore the importance of glioma p53 genotype for predicting tumor response to p53-based gene therapy.
Council on drugs. List No. 88. New names
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hospital characteristics and quality of care
Authors: E. B. Keeler
Journal: JAMA (1992)

<h3>Objective.</h3> —To compare quality of care measured by explicit criteria, implicit review, and sickness-adjusted outcomes at different types of hospitals. <h3>Design.</h3> —Further analysis of data retrospectively abstracted from medical records to evaluate the effects of prospective payment on quality of care for hospitalized Medicare patients. <h3>Setting.</h3> —Hospitals in five states were sampled to represent the national Medicare admissions along many dimensions. <h3>Patients.</h3> —A total of 14008 elderly patients with one of the following five diseases: congestive heart failure, acute myocardial infarction, pneumonia, stroke, or hip fracture. These patients were randomly sampled from those with these diseases in 297 hospitals in two time periods, 1981 to 1982 and 1985 to 1986. <h3>Outcome Measures.</h3> —Explicit criteria, implicit review, and mortality within 30 days of admission adjusted for sickness at admission. <h3>Results.</h3> —Quality of care ratings for hospital types are similar using explicit criteria, implicit review, and outcomes adjusted for sickness at admission. Quality differences between types of hospitals were large, with the lowest group estimated to have four percentage points higher mortality than major teaching hospitals in a cohort of patients with average mortality of 16%. Quality varies from state to state, but teaching, larger, and more urban hospitals have better quality in general than nonteaching, small, and rural hospitals. Hospital quality persists overtime, but small nonteaching hospitals narrowed the gap with better quality hospitals between 1981 and 1986. <h3>Conclusions.</h3> —The different measures led to consistent and plausible relationships between quality and hospital characteristics. Thus, valid information about hospital quality can be obtained. We need to develop ways to use such information to improve care. (<i>JAMA</i>. 1992;268:1709-1714)
AB0199 IGG Subclasses of Autoantibodies Directed against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A and their Clinical Relevance
Authors: J. Guenther, A. Kill, M.O. Becker, E. Siegert, H. Heidecke, G. Riemekasten
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> IgG4-related diseases are often characterized by a generalized inflammatory fibrosis which is also present in patients suffering from systemic sclerosis (SSc). Recent findings indicate the importance of autoantibodies (Aabs) against the angiotensin II receptor type 1 (AT1R) and the endothelin receptor type A (ETAR) in the pathogenesis of SSc. <h3>Objectives</h3> Aim of the study was to analyse associations between the serum levels of anti-AT1R/ETAR IgG sublasses of SSc patients and their clinical features in order to determine a possible role of certain subclasses as markers for disease manifestations. <h3>Methods</h3> Sera from 91 SSc patients, 59 patients suffering from systemic lupus erythematosus (SLE), and 199 healthy donors were analysed for the levels of anti-AT1R and anti-ETAR Aabs as well as for the different anti-AT1R and anti-ETAR IgG subclasses by ELISA. The results were associated with clinical manifestations using Mann-Whitney test and correlated with the time since onset of disease manifestations by Spearman correlation test. <h3>Results</h3> IgG3 followed by IgG1 was found to show highest anti-AT1R/ETAR Aab levels in all analyzed groups, in which SSc patients as well as SLE patients had higher IgG1 and IgG3 anti-AT1R/ETAR Aab levels as compared to healthy donors. Comparing SLE and SSc patients IgG1 and IgG3 showed a bit higher anti-AT1R/ETAR Aab level in SLE. Within the SSc group patients with diffuse SSc had higher anti-AT1R/ETAR IgG3 levels as compared to those with limited disease or overlap forms. Correlation analysis with SSc-related clinical manifestations revealed that levels of anti-AT1R/ETAR IgG3 negatively correlated with time since onset of Raynaud9s phenomenon, and with time since first detection of pulmonary arterial hypertension. Of note, there were negative correlations between levels of anti-AT1R/ETAR IgG3 levels and diffusion capacity of the lung for carbon monoxide (DLCO) as well as between anti-AT1R/ETAR IgG3 levels and forced vital capacity (FVC) values (p=0.02/0.07 and p=0.01/0.03, respectively). <h3>Conclusions</h3> Interestingly, not IgG4 but IgG3 showed highest anti-AT1R/ETAR Aab levels when compared to other IgG subclasses. However, in SSc patients, anti-AT1R/ETAR IgG3 levels are strongly correlated to certain disease manifestations, whereby high anti-AT1R/ETAR IgG3 levels are associated with low DLCO and FVC indicating deterioration of lung function. According to these findings high anti-AT1R/ETAR IgG3 levels could predict for lung function deterioration and represent a new marker for SSc complications. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3699
Canadian Journal of Surgery, Toronto
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LATENT ASTIGMATISM.
Authors: HORACE M. STARKEY
Journal: JAMA (1895)

For a number of years the conviction has been deepening in the mind of the writer that latent astigmatism plays a much more important rôle in the production of asthenopia than is usually supposed, if one may judge from the attention given to this subject in text-books and monographs. This conviction has been more decided, since it has become more common to give patients lenses correcting the apparent error, to be worn continuously for one or more days, after which another test of the refraction is made. Some of the members of this Section may remember that the writer one year ago mentioned with praise the practice, common with some ophthalmologists, of giving lenses, not only spheres but cylinders, to patients to be worn a few days for trial before writing the prescription for permanent glasses. Again, your attention is called to this procedure with the certainty that no one
THE CHANGING CONCEPTS IN PATHOLOGY
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Errors in Abstract, Results Section, and Table 2
Authors: Krisda Chaiyachati, David Grande, Michael Crescenz
Journal: JAMA Internal Medicine (2018)

Krisda H. Chaiyachati, MD, MPH, MSHP; Rebecca A. Hubbard, PhD; Alyssa Yeager, MD; Brian Mugo, MD; Stephanie Lopez, MS; Elizabeth Asch, BS; Catherine Shi, BSN; Judy A. Shea, PhD; Roy Rosin, MBA; David Grande, MD, MPA
Bullous scabies
Authors: S. F. Bean
Journal: JAMA (1974)

SCABIES is caused by the itch mite,<i>Sarcoptes scabiei</i>. The disease is very contagious and produces intractable itching that is most common at night. The disease affects infants and children as well as adults, with epidemics occurring at intervals of about 15 years. Several reports have emphasized the increase in the number of cases of scabies within the past few years.<sup>1-3</sup>Orkin,<sup>3</sup>in a comprehensive survey, showed that a progressive increase in scabies had occurred in many parts of the world, although at the time of his report the United States and Canada had been spared this increase. Now, however, scabies is seen frequently throughout the United States. While scabies in the adult may be easily diagnosed, infants and children with scabies often present a challenging diagnostic problem. This communication describes a child who because of predominance of bullous lesions was thought to have had either pemphigus or
Ambulatory Blood-Pressure Monitoring
Authors: Thomas G. Pickering, Daichi Shimbo, Donald Haas
Journal: New England Journal of Medicine (2006)

Blood pressure is inherently variable, and ambulatory measurements of blood pressure predict clinical outcomes better than do conventional, clinic-based measurements. Ambulatory monitoring can help identify "white-coat" hypertension, as well as patients whose blood pressure does not decrease the normal amount during the night. Ambulatory blood-pressure monitoring is practical, can lead to a reduction in health care costs, and can provide improved estimates of true blood pressures to guide decisions about treatment.
Sulfadiazine
Authors: Maxwell Finland
Journal: JAMA (1984)

Sulfadiazine (2-sulfanilamidopyrimidine), the pyrimidine analogue of sulfapyridine and sulfathiazole, is one of a group of heterocyclic derivatives of sulfanilamide synthesized by Roblin and his co-workers.<sup>1</sup>Laboratory studies on animals indicated that this drug has less toxicity than sulfapyridine and sulfathiazole and is highly effective against experimental infections with common pathogens.<sup>2</sup>Preliminary observations in this clinic<sup>3</sup>and in a number of others in which sulfadiazine was made available<sup>4</sup>indicated that this drug was worthy of extensive trial in the therapy of human bacterial infections. This paper deals mainly with a report of the clinical use of sulfadiazine in 446 adult patients treated at the Boston City Hospital prior to March 1, 1941. The results of laboratory studies will be reviewed briefly. <h3>ANIMAL EXPERIMENTS</h3> Feinstone and his associates<sup>2</sup>have shown that sulfadiazine is considerably less toxic than sulfapyridine or sulfathiazole both in acute experiments on mice and
DOCTOR DEAN-DOCTOR PRESIDENT
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE RUSH MONUMENT.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal